Fiche publication
Date publication
octobre 2024
Journal
Journal of hematology & oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DELVA Laurent
,
Dr AUCAGNE Romain
Tous les auteurs :
Sheridan M, Maqbool MA, Largeot A, Clayfield L, Xu J, Moncaut N, Sellers R, Whittle J, Paggetti J, Iqbal M, Aucagne R, Delva L, Baker SM, Lie-A-Ling M, Kouskoff V, Lacaud G
Lien Pubmed
Résumé
The epigenetic factors KAT6A (MOZ/MYST3) and KMT2A (MLL/MLL1) interact in normal hematopoiesis to regulate progenitors' self-renewal. Both proteins are recurrently translocated in AML, leading to impairment of critical differentiation pathways in these malignant cells. We evaluated the potential of different KAT6A therapeutic targeting strategies to alter the growth of KAT6A and KMT2A rearranged AMLs.
Mots clés
Leukemia, Myeloid, Acute, genetics, Animals, Myeloid-Lymphoid Leukemia Protein, genetics, Humans, Mice, Histone-Lysine N-Methyltransferase, genetics, Histone Acetyltransferases, genetics, Gene Rearrangement, Cell Line, Tumor
Référence
J Hematol Oncol. 2024 10 8;17(1):91
